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httpContrast alternatives for iodinated contrast allergy
and renal dysfunction: Options and limitations
Gregory J. Nadolski, MD, and S. William Stavropoulos, MD, Philadelphia, Pa
Diagnostic angiography and vascular interventions make routine use of iodinated contrast material (ICM). Patients with
renal disease or contrast allergy pose limitations on the use of ICM. In such cases, alternative contrast media may be used
to carry out the procedure. Current alternatives include carbon dioxide, gadolinium, and dilute ICM. Each of these
alternatives has its own unique features and limitations. In the present review article, the current alternatives to ICM are
explored, with a focus on the applications and restrictions of each. (J Vasc Surg 2013;57:593-8.)Patients with impaired renal function or contrast allergy
pose a challenge to the safe and effective performance of
diagnostic angiography and vascular interventions using
iodinated contrast media. Despite the development of
low and iso-osmolar iodinated contrast material (ICM)
and the institution of hydration protocols, patients with
chronic kidney disease (CKD), especially those with con-
comitant diabetes, remain at risk for contrast-induced
nephropathy (CIN).1,2 Contrast allergies are another po-
tential barrier to the use of iodinated contrast for vascular
interventions.3,4 Although premedication with steroids
and antihistamines allows iodinated contrast to be used
safely in many allergic patients, occasionally patients pres-
ent for procedures without having taken effective prophy-
laxis or having failed premedication in the past. Given the
prevalence of the scenarios in which ICM poses potential
serious risk to the patient, a strong interest remains in
the use of alternative contrast media. Our purpose is to
brieﬂy review ICM contrast allergies and nephrotoxicity
and then to review the applications and limitations of
alternatives to full-strength iodinated contrast, which
include carbon dioxide (CO2), gadolinium, and dilute
iodinated contrast, for patients with CKD and iodinated
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Reviews devoted solely to the chemical and physical
properties of iodinated contrast have been published.5-8
In brief, all ICMs in current use are modiﬁcations of
a 2,4,6-tri-iodinated benzene ring and are classiﬁed based
on the physical and chemical properties of osmolality, ioni-
zation in solution, and chemical structure. Four classes of
contrast are commercially available: ionic monomers,
nonionic monomers, ionic dimers, and nonionic dimers.
Additionally, agents can be classiﬁed by their osmolality
relative to blood and typically are described as high, low,
or iso-osmolar. Once administered intravascularly, these
agents are rapidly distributed in the body and are excreted
largely unmetabolized in the urine.
Allergic reactions to ICM. Allergic reactions to ICM
occur. They typically are described as anaphylactoid
because they have the features of type 4 hypersensitivity
reactions but do not occur through an immunoglobulin
E-mediated pathway in most cases. In fact, the exact mech-
anism remains unknown.9 Mild anaphylactic reactions to
high-osmolar ionic contrast occur between 4% and 12%,
whereas such reactions occur in only 0.7% to 3% of patients
receiving low-osmolar nonionic contrast.10,11 Severe
anaphylaxis is estimated to occur between 0.1% to 0.4%
with ionic contrast material and 0.02% to 0.04% with
nonionic contrast material.10,12 Attempts to reduce
contrast reactions with steroid prophylaxis (classically
prednisolone 32 mg given 12 and 2 hours before the
procedure) are beneﬁcial for mild and moderate reactions
but less so for severe anaphylaxis.13,14 Additionally,
breakthrough reactions occur in some patients.4
Contrast-induced nephropathy. Contrast-induced
nephropathy is deﬁned as acute kidney injury attributable
to the administration of iodinated contrast. The exact deﬁ-
nition of acute kidney injury for diagnosing CIN and
the temporal relationship of contrast administration are
still debated. Some data support an absolute rise in serum
creatinine $0.5 within 48 hours to be a reasonable593
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result of direct tubule toxicity and hypoxia caused by
reduced blood ﬂow and subsequent generation of reactive
oxygen species.17 The incidence of CIN is related to the
dose of ICM, the route of administration (intra-arterial >
intravenous), and patient factors, of which CKD with an
estimated glomerular ﬁltration rate (eGFR) <60 mL/min
is the most important.17,18 Studies have tried to identify
the maximum amount of CM that can safely be injected
during percutaneous coronary interventions, suggesting
possible limits of ICM dose in grams of iodine equal to the
eGFRorkeeping the ratioof theCMvolume to the creatinine
clearance <3.7. However, a safe dose of ICM has not been
established for patients with CKD.19 Multiple meta-analyses
regarding prevention of CIN have been conducted using
hydration protocols and various oral medications thought to
be renal protective. Most authors conclude that intravenous
hydration is of some beneﬁt. Comparison of hydration
protocols and oral agents is beyond the scope of this review.
For a more detailed review, see van der Molen et al.2,19
ALTERNATIVE CONTRAST AGENTS
Carbon dioxide
Principles of carbon dioxide and its advantages.
Carbon dioxide (CO2) is a highly soluble, invisible gas.
When injected into vessels, it brieﬂy displaces the blood
before it is rapidly dissolved and eliminated through exha-
lation.20 The unique properties of CO2 give it several
advantages over other contrast media. Foremost, CO2 is
nonallergenic and nonnephrotoxic, making it safe for use in
patients with either contrast allergy or kidney disease.21-25
Essentially unlimited volumes of CO2 can be used,
assuming sufﬁcient time is allowed for the gas to be elim-
inated from the body. Carbon dioxide even is safe in
patients with chronic lung disease with CO2 retention, as
long as additional time is taken between injections to allow
for the gas to be cleared by the lungs.26 Further beneﬁts
include its low viscosity relative to blood, which can aid in
the detection of subtle bleeding.27 Carbon dioxide’s low
viscosity additionally can improve visualization of small
collateral vessels and aid in identifying distal reconstitution
in patients with peripheral arterial disease.21 Lastly,
medical-grade CO2 is very inexpensive compared with
iodinated contrast and is readily available.
Limitations and complications of CO2. However,
CO2 is not without limitations. Given the possibility of
neurotoxicity, CO2 cannot be injected or allowed to enter
the cerebral circulation.28 Thus, CO2 should be used only
for infradiaphragmatic arteriography. Central venography
above the diaphragm is still permissible with CO2 and, in
fact, may be more sensitive for detecting central venous
stenosis.26 The rare complication of air trapping, or vapor
lock, is another limitation. If an excessive volume of CO2 is
injected at once or the blood–gas interface is reduced,
normal dissolution of CO2 into the bloodstream may
not occur. The undissolved bolus of gas may then im-
pede blood ﬂow and produce ischemia.29 Nondependentlocations such as aortic aneurysms, the pulmonary outﬂow
tract, and the mesenteric vessels are most at risk.30 Typi-
cally, vapor lock can be broken by changing the patient’s
position or by aspiration of the CO2. If CO2 arteriography
is being used near or in a vessel at risk for vapor lock,
periodic ﬂuoroscopy between injections is advisable. If
residual gas is seen between injections, the patient’s posi-
tion should brieﬂy be changed to move the CO2 bolus into
a different vessel to allow dissolution.31 The theoretical risk
of air trapping increases with introduction of less soluble
gases from room air contamination and the use of nitrous
oxide as an inhaled anesthetic. Nitrous oxide may dissolve
out of the soft tissues and into the intravascular CO2 bolus,
rapidly increasing its volume and its potential to create
a vapor lock.29
Another barrier is ease of use. Because a dedicated CO2
injector or bag delivery system is not available in the
United States, practitioners may be unfamiliar with admin-
istration of CO2. Most physicians use a system of tandem
three-way stopcocks or a three-way stopcock and a ﬂow
switch (Fig 1). Contamination with less soluble room air
could occur if a stopcock or ﬂow switch is left open.26
Because both gases are invisible, contamination of CO2
with room air is impossible to detect. Special attention
must be given to purging syringes of air and, once ﬁlled
with CO2, not allowing valves to be left open. Carbon
dioxide has been shown to accurately measure vessel diam-
eter (Fig 2). However, improper injection of CO2 can lead
to errors in measurement.21,32 CO2 is buoyant relative to
blood and therefore rises to the nondependent portion of
the vessel. If insufﬁcient volumes of CO2 are injected
into large vessels, the operator may underestimate the
true size of the vessel (Fig 3). Alternatively, if the bolus is
delivered in an explosive manner, the operator may overes-
timate vessel diameter.33
Optimizing image quality with CO2. Unfamiliar
users may be uncertain of how to optimize image quality
for their procedures. With the development of digital
subtraction angiography and image stacking software, use
of CO2 as a contrast agent has became a viable option.
Hawkins21 ﬁrst reported his pioneering use of CO2 as an
intravascular contrast agent in the early 1980s. Most
modern angiography suites come with preinstalled settings
to optimize image quality for CO2 angiography. Typically,
inversion opaciﬁcation software is used with a frame rate of
three to six per second using a 60-ms exposure time.26 To
prevent explosive delivery of CO2, blood should be purged
from the catheter with CO2 before subtraction angiog-
raphy is performed. A less explosive injection will reduce
patient discomfort and thus motion artifact. Proper injec-
tion rate also reduces fragmentation of the CO2 bolus,
which, when combined with the buoyancy of CO2, can
give the illusion of a stenosis.34 If fragmentation occurs,
image stacking may be used to improve image quality. If
stacking is unavailable or does not resolve the problem,
a repeat angiogram with a longer injection (and larger
volume of CO2) can be performed.
26 Vessel-speciﬁc
protocols for CO2 arteriography are beyond the scope of
Fig 2. Diagnosis of May-Thurner syndrome and treatment using carbon dioxide (CO2). Cavogram and bilateral iliac
venogram demonstrate normal right iliac vein (A) and extrinsically compressed left common iliac vein (B). Accurate
estimation of vessel size for stent placement can be obtained with CO2. Poststent venogram demonstrates brisk ﬂow
into the inferior vena cava with appropriately sized and properly apposed stent in the left common iliac (C).
Fig 1. A, Tandem three-way stopcocks with extension tubing and 60-mL syringe used to administer carbon dioxide
(CO2) for angiography. B, Filling the syringe with CO2. C, Disconnect syringe from tubing that is connected to the
CO2 canister. Close three-way stopcock. The syringe is not ready to connect to the diagnostic catheter.
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can be found in Hawkins et al.26
Dilute iodinated contrast
Advantages and use of angiography in patients with
CKD. Another alternative for patients with CKD under-
going vascular interventions is dilute ICM. The principaladvantage of using diluted ICM is the operator’s familiarity
with administration during diagnostic angiography and
endovascular procedures. Its use has primarily been studied
in dialysis ﬁstulography and venous mapping. In 28 patients
undergoing venous mapping, Won et al35 demonstrated no
signiﬁcant difference in eGFR at baseline and 4 days after
receiving 10 to 15mL of iodinated contrast diluted 1:1 with
Fig 3. Leg arteriogram demonstrating pseudostenosis. A, Left leg
arteriogram depicting stenosis in left common femoral artery and
proximal left superﬁcial femoral artery (arrows). B, Repeat arte-
riogram with the patient’s leg elevated and with more forceful
injection showing the suspected lesion in the common femoral
artery was a pseudostenosis, while the stenosis of the superﬁcial
femoral artery was overestimated. Both occurred due to poor
injection technique and underﬁlling of the vessel.
Fig 4. Use of carbon dioxide (CO2) in conjunction with dilute
contrast. Aortogram with CO2 identiﬁes single left renal artery
(white arrow) and large hypervascular left renal mass (black arrow).
Dilute contrast was used for selective renal arteriogram before
embolization of the mass (image not shown).
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which resolved within 1 week.35 Similarly, patients with
stage 4 kidney disease (eGFR <30 mL/min) undergoing
ﬁstulography and intervention who are hydrated with
a weight-based bicarbonate protocol and receive<20mL of
ICM diluted 1:2 with normal saline have a reported CIN
incidence of 5.5%.36
Limitations of dilute contrast. Several limitations of
dilute ICM exist. First, it cannot be used as an alternative
in patients with anaphylactic allergy to ICM. Second, the
operator is still limited with regard to the total volume of
contrast that can safely be used without putting patients
at risk for CIN. Lastly, if overly dilute, the contrast may
not be rendered optimal image quality in large vessels
within the abdomen or thorax. Given the limited advan-
tages of dilute ICM, we typically reserve its use for extremity
angiography, ﬁstulography, and selective arteriography as
a supplemental tool for use with CO2 (Figs 4 and 5).
37
Gadolinium
Nephrogenic systemic sclerosis and the limited role
of gadolinium. Gadoliniumoncewas heralded as an alterna-
tive contrast agent in patients with CKD. Since its association
with the disease nephrogenic systemic ﬁbrosis (NSF) in 2006,
its use as an angiographic agent in patients with CKD has
appropriately declined rapidly.38
Nephrogenic systemic ﬁbrosis is an illness that presents
with ﬁrm, erythematous, and indurated plaques of the skinassociated with subcutaneous edema involving the extrem-
ities.39 It can progress to ﬂexion contractures with limited
range of motion, pain, paresthesias, and/or severe pruritus.
Currently, no effective treatment of NSF is available.39
Knowledge of NSF’s pathogenesis, risk factors for
acquiring it, and its exact relationship to gadolinium is still
not completely elucidated.39,40 Studies suggest that slow
excretion of gadolinium-based contrast media in patients
with severe renal impairment allows lower-stability gadoli-
nium chelates to dissociate, releasing free gadolinium,
which incites the disease.41
The overall incidence of NSF is difﬁcult to assess but
may be as high as 3% to 7% in patients with severe CKD.42
In a study of 33 patients presenting with NSF, all patients
had eGFR <15 mL/min at the time of gadolinium admin-
istration. Four of these patients had received gadolinium
during arteriography.40 Although the incidence is low
and the exact relationship between gadolinium and NSF
is not fully known, its use in patients with severe CKD
(eGFR <15 mL/min) is not recommended by the United
States Food and Drug Administration and the American
College of Radiology.43 Furthermore, studies have shown
gadolinium chelates to be nephrotoxic in patients with stage
3 and 4 CKD (eGFR <60 mL/min) when used in equiva-
lent X-ray attenuating doses with a reported incidence of
gadolinium CIN of 1.9%.1,44,45 In fact, the use of gadoli-
nium as an alternative contrast agent in patients with any
Fig 5. Use of dilute contrast to supplement carbon dioxide (CO2)
in upper extremity ﬁstulogram performed in a patient with residual
renal function. Retrograde access to the ﬁstula was achieved
directed toward arterial anastomosis. The radial artery was selected
with a Binkert catheter. A, Fistulogram performed using dilute
iodinated contrast material demonstrating two tandem stenoses in
the perianastomotic vein (black arrows). B, Postangioplasty ﬁstu-
logram with dilute iodinated contrast material (ICM) demon-
strating no residual stenosis. The remainder of the ﬁstulogram,
including central venography, was completed using CO2 (image
not shown).
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consensus groups.1,44 In summary, the application of gado-
linium as an ICM alternative for angiography is essentially
limited to patients with normal renal function who have
anaphylactic reaction to ICM.
Limitations of gadolinium in patients with normal
renal function. Even in this scenario, gadoliniumhas several
challenges and limitations. The physical properties of gadoli-
nium are different from those of iodine, and the contrast
produced by gadolinium chelates using standard angio-
graphic settings is similar to that of dilute contrast. Adjust-
ments to the peak voltage of the X-ray source can result in
contrast similar to that of full-strength ICM.46 Gadolinium
is in such low concentration in current commercially available
chelates that it cannot be visualized under ﬂuoroscopy. Thus,
all test injections must be performed using digital subtraction
angiography. The total volumeof gadolinium chelate injected
is typically limited to 0.3 mmol/kg to prevent nephrotoxicity
(approximately between 42 and 56 mL for a 70-kg man
depending on the chelate used).1,47
SUMMARY
Impaired renal function and allergic reactions can limit
the typical use of ICM for diagnostic arteriography and
vascular interventions. Several alternatives, each with its
unique beneﬁts and limitations, exist for use in these
scenarios. Patients with normal renal function but contrast
allergy ideally should receive appropriate prophylaxis, and
ICM can be used. If prophylaxis cannot be administeredor has been ineffective in the past, CO2 is our preferred
alternative contrast, with gadolinium being reserved for
arteriography of the arch vessels. In the setting of CKD,
our preferred alternative contrast is CO2, which may be
supplemented with a limited volume of ICM, which can
be diluted to provide a greater volume. We do not recom-
mend the use of gadolinium in patients with CKD.
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